These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 29931399)
1. Tyrosine Kinase Inhibitor-Induced Hypertension. Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399 [TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. Budolfsen C; Faber J; Grimm D; Krüger M; Bauer J; Wehland M; Infanger M; Magnusson NE Curr Vasc Pharmacol; 2019; 17(6):618-634. PubMed ID: 30706818 [TBL] [Abstract][Full Text] [Related]
3. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. León-Mateos L; Mosquera J; Antón Aparicio L Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721 [TBL] [Abstract][Full Text] [Related]
6. Management of hypertension in angiogenesis inhibitor-treated patients. Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Kruzliak P; Novák J; Novák M Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915 [TBL] [Abstract][Full Text] [Related]
8. Use of Antihypertensive Drugs in Neoplastic Patients. Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339 [TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778 [TBL] [Abstract][Full Text] [Related]
10. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors. Leon LA; Antón-Aparicio LM Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162293 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment. Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083 [TBL] [Abstract][Full Text] [Related]
13. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397 [TBL] [Abstract][Full Text] [Related]
14. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Vaziri SA; Kim J; Ganapathi MK; Ganapathi R Curr Oncol Rep; 2010 Mar; 12(2):102-8. PubMed ID: 20425594 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380 [TBL] [Abstract][Full Text] [Related]
18. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Funakoshi T; Latif A; Galsky MD Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273 [TBL] [Abstract][Full Text] [Related]
20. Proteinuria and hypertension with tyrosine kinase inhibitors. Kandula P; Agarwal R Kidney Int; 2011 Dec; 80(12):1271-7. PubMed ID: 21900879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]